Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Risperidone | 19 | 2018 | 60 | 7.860 |
Why?
|
| Depressive Disorder, Major | 16 | 2021 | 400 | 5.790 |
Why?
|
| Antipsychotic Agents | 23 | 2024 | 374 | 5.050 |
Why?
|
| Bone Density | 8 | 2023 | 312 | 2.880 |
Why?
|
| Weight Gain | 10 | 2023 | 401 | 2.770 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 5 | 2023 | 215 | 1.910 |
Why?
|
| Sertraline | 2 | 2024 | 44 | 1.780 |
Why?
|
| Depression | 6 | 2024 | 1224 | 1.770 |
Why?
|
| Bone and Bones | 4 | 2017 | 262 | 1.770 |
Why?
|
| Anxiety Disorders | 5 | 2019 | 676 | 1.710 |
Why?
|
| Adolescent | 48 | 2024 | 19030 | 1.670 |
Why?
|
| Anxiety | 4 | 2024 | 955 | 1.480 |
Why?
|
| Ferritins | 5 | 2024 | 96 | 1.400 |
Why?
|
| Autism Spectrum Disorder | 3 | 2023 | 375 | 1.330 |
Why?
|
| Fluoxetine | 2 | 2024 | 43 | 1.200 |
Why?
|
| alpha7 Nicotinic Acetylcholine Receptor | 2 | 2018 | 57 | 1.190 |
Why?
|
| Sexual Behavior | 2 | 2021 | 235 | 1.130 |
Why?
|
| Anemia, Iron-Deficiency | 2 | 2024 | 132 | 1.100 |
Why?
|
| Child | 36 | 2024 | 24144 | 1.040 |
Why?
|
| Hyperprolactinemia | 3 | 2017 | 17 | 1.010 |
Why?
|
| Puberty | 2 | 2024 | 94 | 1.000 |
Why?
|
| Absorptiometry, Photon | 8 | 2017 | 178 | 0.970 |
Why?
|
| Iron | 4 | 2024 | 261 | 0.960 |
Why?
|
| Metformin | 2 | 2023 | 148 | 0.940 |
Why?
|
| Male | 48 | 2024 | 59901 | 0.940 |
Why?
|
| Metabolic Syndrome | 3 | 2014 | 329 | 0.930 |
Why?
|
| Body Height | 1 | 2024 | 210 | 0.870 |
Why?
|
| Nutrition Surveys | 1 | 2024 | 289 | 0.840 |
Why?
|
| Autonomic Nervous System | 2 | 2023 | 45 | 0.840 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2024 | 340 | 0.820 |
Why?
|
| Mental Disorders | 5 | 2019 | 826 | 0.780 |
Why?
|
| Humans | 61 | 2024 | 122998 | 0.770 |
Why?
|
| Young Adult | 15 | 2023 | 8840 | 0.770 |
Why?
|
| Hyperglycemia | 1 | 2023 | 218 | 0.750 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2021 | 678 | 0.750 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2021 | 40 | 0.750 |
Why?
|
| Female | 40 | 2024 | 65310 | 0.750 |
Why?
|
| Antidepressive Agents | 1 | 2023 | 287 | 0.720 |
Why?
|
| Movement Disorders | 1 | 2023 | 221 | 0.700 |
Why?
|
| Migraine Disorders | 2 | 2020 | 64 | 0.700 |
Why?
|
| Steroids | 2 | 2019 | 203 | 0.650 |
Why?
|
| Catatonia | 1 | 2019 | 12 | 0.650 |
Why?
|
| Nephrotic Syndrome | 1 | 2019 | 47 | 0.640 |
Why?
|
| Body Mass Index | 11 | 2023 | 1542 | 0.630 |
Why?
|
| Cyclosporine | 1 | 2019 | 146 | 0.620 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 2 | 2015 | 44 | 0.620 |
Why?
|
| Sexual Maturation | 1 | 2018 | 48 | 0.610 |
Why?
|
| Calcium Carbonate | 1 | 2017 | 11 | 0.600 |
Why?
|
| Cholecalciferol | 1 | 2017 | 22 | 0.590 |
Why?
|
| Adult Survivors of Child Adverse Events | 1 | 2017 | 15 | 0.570 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2017 | 65 | 0.570 |
Why?
|
| Lumbar Vertebrae | 4 | 2023 | 107 | 0.550 |
Why?
|
| Antifungal Agents | 1 | 2019 | 293 | 0.540 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2017 | 69 | 0.540 |
Why?
|
| Toxoplasma | 1 | 2016 | 10 | 0.530 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2023 | 771 | 0.530 |
Why?
|
| Basal Ganglia Diseases | 1 | 2016 | 27 | 0.530 |
Why?
|
| Toxoplasmosis | 1 | 2016 | 19 | 0.530 |
Why?
|
| Central Nervous System Stimulants | 3 | 2013 | 125 | 0.530 |
Why?
|
| Body Fat Distribution | 1 | 2016 | 28 | 0.520 |
Why?
|
| Bacteroidetes | 1 | 2015 | 20 | 0.510 |
Why?
|
| Firmicutes | 1 | 2015 | 22 | 0.510 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 5031 | 0.510 |
Why?
|
| Problem Behavior | 1 | 2016 | 36 | 0.500 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 33 | 0.500 |
Why?
|
| Cross-Sectional Studies | 7 | 2024 | 3359 | 0.500 |
Why?
|
| Serotonin Antagonists | 1 | 2015 | 24 | 0.500 |
Why?
|
| Polymorphism, Genetic | 3 | 2021 | 810 | 0.490 |
Why?
|
| Comorbidity | 5 | 2023 | 1498 | 0.490 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 849 | 0.480 |
Why?
|
| Suicide, Attempted | 1 | 2016 | 131 | 0.470 |
Why?
|
| Body Composition | 1 | 2017 | 513 | 0.470 |
Why?
|
| Adiposity | 1 | 2015 | 191 | 0.460 |
Why?
|
| Gene Deletion | 1 | 2017 | 793 | 0.460 |
Why?
|
| Psychotropic Drugs | 1 | 2015 | 125 | 0.450 |
Why?
|
| Electroconvulsive Therapy | 2 | 2004 | 66 | 0.430 |
Why?
|
| Pilot Projects | 5 | 2021 | 1386 | 0.430 |
Why?
|
| Obesity | 4 | 2023 | 2227 | 0.420 |
Why?
|
| Prolactin | 4 | 2016 | 103 | 0.420 |
Why?
|
| Cytokines | 1 | 2018 | 1280 | 0.420 |
Why?
|
| Overweight | 1 | 2016 | 358 | 0.420 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2017 | 469 | 0.400 |
Why?
|
| Bipolar Disorder | 1 | 2015 | 347 | 0.400 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2011 | 42 | 0.390 |
Why?
|
| Isoxazoles | 1 | 2011 | 31 | 0.370 |
Why?
|
| Dextroamphetamine | 1 | 2010 | 5 | 0.370 |
Why?
|
| Methylphenidate | 1 | 2010 | 55 | 0.360 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2021 | 804 | 0.350 |
Why?
|
| Glycine | 1 | 2010 | 160 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2024 | 1684 | 0.330 |
Why?
|
| Prospective Studies | 5 | 2019 | 6023 | 0.330 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2009 | 38 | 0.330 |
Why?
|
| Algorithms | 1 | 2015 | 1596 | 0.310 |
Why?
|
| Leptin | 1 | 2009 | 211 | 0.310 |
Why?
|
| Linear Models | 3 | 2017 | 671 | 0.310 |
Why?
|
| Treatment Outcome | 9 | 2023 | 12087 | 0.310 |
Why?
|
| Child, Preschool | 7 | 2018 | 13819 | 0.300 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2021 | 202 | 0.300 |
Why?
|
| Pyrimidines | 1 | 2011 | 374 | 0.300 |
Why?
|
| Hypertriglyceridemia | 1 | 2009 | 99 | 0.300 |
Why?
|
| Emotions | 3 | 2019 | 364 | 0.270 |
Why?
|
| Longitudinal Studies | 3 | 2021 | 1313 | 0.270 |
Why?
|
| Demography | 2 | 2017 | 239 | 0.250 |
Why?
|
| Imagination | 2 | 2008 | 17 | 0.240 |
Why?
|
| Sex Characteristics | 2 | 2017 | 312 | 0.240 |
Why?
|
| Human Growth Hormone | 1 | 2024 | 74 | 0.230 |
Why?
|
| Methohexital | 1 | 2003 | 3 | 0.230 |
Why?
|
| Myasthenia Gravis | 1 | 2004 | 71 | 0.230 |
Why?
|
| Methyl Ethers | 1 | 2003 | 23 | 0.220 |
Why?
|
| Mental Processes | 1 | 2003 | 41 | 0.220 |
Why?
|
| Anesthetics, Intravenous | 1 | 2003 | 47 | 0.220 |
Why?
|
| Anesthetics, Inhalation | 1 | 2003 | 46 | 0.220 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2023 | 26 | 0.220 |
Why?
|
| Severity of Illness Index | 4 | 2018 | 2837 | 0.210 |
Why?
|
| Acceptance and Commitment Therapy | 2 | 2020 | 40 | 0.200 |
Why?
|
| Quinolones | 2 | 2013 | 54 | 0.200 |
Why?
|
| Cohort Studies | 2 | 2024 | 4705 | 0.200 |
Why?
|
| Sex Factors | 2 | 2019 | 1254 | 0.200 |
Why?
|
| Orgasm | 1 | 2021 | 7 | 0.200 |
Why?
|
| Receptor, Serotonin, 5-HT2A | 1 | 2021 | 9 | 0.200 |
Why?
|
| Interpersonal Relations | 1 | 2003 | 229 | 0.190 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 1845 | 0.190 |
Why?
|
| Mental Health | 1 | 2024 | 346 | 0.190 |
Why?
|
| Qualitative Research | 1 | 2024 | 522 | 0.180 |
Why?
|
| Adult | 10 | 2023 | 28980 | 0.180 |
Why?
|
| Piperazines | 2 | 2013 | 229 | 0.180 |
Why?
|
| Double-Blind Method | 2 | 2017 | 1585 | 0.180 |
Why?
|
| Adolescent Behavior | 1 | 2021 | 171 | 0.170 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2021 | 372 | 0.170 |
Why?
|
| Drug Therapy, Combination | 2 | 2015 | 1148 | 0.170 |
Why?
|
| Avoidance Learning | 1 | 2019 | 56 | 0.160 |
Why?
|
| Problem-Based Learning | 1 | 2019 | 68 | 0.160 |
Why?
|
| Respiratory Sinus Arrhythmia | 1 | 2018 | 9 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1417 | 0.160 |
Why?
|
| Risk Factors | 4 | 2019 | 9974 | 0.160 |
Why?
|
| Prevalence | 2 | 2017 | 2394 | 0.160 |
Why?
|
| Permeability | 1 | 2018 | 118 | 0.160 |
Why?
|
| Time Factors | 3 | 2018 | 6198 | 0.150 |
Why?
|
| Drug Resistance | 1 | 2019 | 256 | 0.150 |
Why?
|
| Seizures | 1 | 2003 | 871 | 0.150 |
Why?
|
| Biomarkers | 2 | 2021 | 2940 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2017 | 2041 | 0.150 |
Why?
|
| Calcium, Dietary | 1 | 2017 | 37 | 0.150 |
Why?
|
| Inflammation | 2 | 2021 | 1400 | 0.140 |
Why?
|
| Interleukin-6 | 2 | 2021 | 393 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2018 | 515 | 0.130 |
Why?
|
| Brain | 2 | 2008 | 2943 | 0.130 |
Why?
|
| Asymptomatic Infections | 1 | 2016 | 33 | 0.130 |
Why?
|
| Iron Metabolism Disorders | 1 | 2015 | 13 | 0.130 |
Why?
|
| Aggression | 2 | 2023 | 226 | 0.130 |
Why?
|
| Regression Analysis | 1 | 2017 | 771 | 0.130 |
Why?
|
| Interview, Psychological | 1 | 2016 | 97 | 0.130 |
Why?
|
| Serologic Tests | 1 | 2016 | 119 | 0.130 |
Why?
|
| Social Perception | 2 | 2008 | 57 | 0.130 |
Why?
|
| Intra-Abdominal Fat | 1 | 2016 | 51 | 0.130 |
Why?
|
| Statistics as Topic | 1 | 2016 | 252 | 0.120 |
Why?
|
| X-Ray Microtomography | 1 | 2015 | 79 | 0.120 |
Why?
|
| Blood Glucose | 3 | 2023 | 1113 | 0.120 |
Why?
|
| Phantoms, Imaging | 1 | 2015 | 126 | 0.120 |
Why?
|
| Logistic Models | 1 | 2019 | 1796 | 0.120 |
Why?
|
| Osteoporosis | 1 | 2015 | 115 | 0.120 |
Why?
|
| Vitamin D | 1 | 2016 | 159 | 0.120 |
Why?
|
| ROC Curve | 1 | 2016 | 556 | 0.120 |
Why?
|
| Dietary Supplements | 1 | 2017 | 471 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2023 | 3259 | 0.110 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2014 | 141 | 0.110 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 940 | 0.110 |
Why?
|
| Radiography | 1 | 2015 | 818 | 0.100 |
Why?
|
| Skinfold Thickness | 1 | 2012 | 32 | 0.100 |
Why?
|
| Prognosis | 2 | 2019 | 4490 | 0.100 |
Why?
|
| Signal Transduction | 1 | 2024 | 4507 | 0.100 |
Why?
|
| Conduct Disorder | 1 | 2011 | 32 | 0.100 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2011 | 3 | 0.100 |
Why?
|
| Paliperidone Palmitate | 1 | 2011 | 4 | 0.100 |
Why?
|
| Sexual Development | 1 | 2011 | 23 | 0.090 |
Why?
|
| Homeostasis | 1 | 2015 | 681 | 0.090 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2011 | 31 | 0.090 |
Why?
|
| Polypharmacy | 1 | 2011 | 40 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 1067 | 0.090 |
Why?
|
| Calcium | 1 | 2016 | 1096 | 0.090 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 182 | 0.090 |
Why?
|
| Pregnancy Outcome | 1 | 2013 | 595 | 0.090 |
Why?
|
| Depressive Disorder | 1 | 2013 | 451 | 0.090 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2011 | 82 | 0.090 |
Why?
|
| Radius | 1 | 2010 | 25 | 0.090 |
Why?
|
| Growth | 1 | 2010 | 105 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2023 | 15931 | 0.080 |
Why?
|
| Psychotic Disorders | 1 | 2011 | 140 | 0.080 |
Why?
|
| Anthropometry | 1 | 2010 | 197 | 0.080 |
Why?
|
| United States | 1 | 2024 | 10595 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2013 | 505 | 0.080 |
Why?
|
| Waist Circumference | 1 | 2009 | 88 | 0.080 |
Why?
|
| Child Behavior Disorders | 1 | 2009 | 68 | 0.080 |
Why?
|
| DNA Primers | 1 | 2009 | 661 | 0.080 |
Why?
|
| Oxygen Radioisotopes | 2 | 2008 | 4 | 0.080 |
Why?
|
| Linkage Disequilibrium | 1 | 2009 | 311 | 0.080 |
Why?
|
| Tic Disorders | 1 | 2009 | 77 | 0.080 |
Why?
|
| Schizophrenic Psychology | 1 | 2008 | 81 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2010 | 182 | 0.070 |
Why?
|
| Cholesterol, HDL | 1 | 2009 | 348 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 730 | 0.070 |
Why?
|
| Gene Frequency | 1 | 2009 | 714 | 0.070 |
Why?
|
| Functional Laterality | 2 | 2008 | 181 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2012 | 638 | 0.070 |
Why?
|
| Alleles | 1 | 2011 | 1602 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2012 | 1314 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 1586 | 0.060 |
Why?
|
| Middle Aged | 4 | 2020 | 25931 | 0.060 |
Why?
|
| Genotype | 1 | 2011 | 2546 | 0.060 |
Why?
|
| Brain Mapping | 2 | 2008 | 397 | 0.060 |
Why?
|
| Schizophrenia | 1 | 2008 | 299 | 0.060 |
Why?
|
| Testosterone | 1 | 2010 | 462 | 0.060 |
Why?
|
| Base Sequence | 1 | 2009 | 3093 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2011 | 1479 | 0.060 |
Why?
|
| Child Psychiatry | 1 | 2024 | 17 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2015 | 6359 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2005 | 211 | 0.060 |
Why?
|
| Aging | 1 | 2011 | 1173 | 0.060 |
Why?
|
| Cognition Disorders | 1 | 2008 | 555 | 0.060 |
Why?
|
| Tomography, Emission-Computed | 1 | 2003 | 43 | 0.060 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2023 | 24 | 0.050 |
Why?
|
| Thinking | 1 | 2003 | 34 | 0.050 |
Why?
|
| Acceleration | 1 | 2023 | 27 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2024 | 158 | 0.050 |
Why?
|
| Awareness | 1 | 2003 | 81 | 0.050 |
Why?
|
| Interviews as Topic | 1 | 2024 | 370 | 0.050 |
Why?
|
| Aripiprazole | 2 | 2013 | 21 | 0.050 |
Why?
|
| Water | 1 | 2003 | 182 | 0.050 |
Why?
|
| Self Concept | 1 | 2003 | 157 | 0.050 |
Why?
|
| Models, Neurological | 1 | 2003 | 204 | 0.050 |
Why?
|
| Social Behavior | 1 | 2003 | 207 | 0.050 |
Why?
|
| Resistin | 1 | 2021 | 36 | 0.050 |
Why?
|
| Nerve Net | 1 | 2003 | 235 | 0.050 |
Why?
|
| Cholesterol | 1 | 2023 | 525 | 0.050 |
Why?
|
| Machine Learning | 1 | 2023 | 213 | 0.040 |
Why?
|
| Psychotherapy, Group | 1 | 2020 | 50 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2003 | 850 | 0.040 |
Why?
|
| Pituitary-Adrenal System | 1 | 2019 | 36 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2019 | 65 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 3090 | 0.040 |
Why?
|
| Cognition | 1 | 2023 | 736 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2021 | 670 | 0.040 |
Why?
|
| Exercise | 1 | 2023 | 809 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 441 | 0.030 |
Why?
|
| Infant | 1 | 2010 | 12286 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 1166 | 0.030 |
Why?
|
| Stress, Psychological | 1 | 2019 | 557 | 0.030 |
Why?
|
| Patient Admission | 1 | 2013 | 184 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 3510 | 0.020 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2013 | 171 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2013 | 226 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2013 | 312 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 3657 | 0.020 |
Why?
|
| Control Groups | 1 | 2008 | 12 | 0.020 |
Why?
|
| Verbal Behavior | 1 | 2008 | 52 | 0.020 |
Why?
|
| Reading | 1 | 2008 | 77 | 0.020 |
Why?
|
| Intention | 1 | 2008 | 93 | 0.020 |
Why?
|
| Aged | 1 | 2004 | 19035 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 2801 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 287 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2008 | 423 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2008 | 923 | 0.010 |
Why?
|
| Pregnancy | 1 | 2013 | 7115 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2013 | 8070 | 0.010 |
Why?
|